Prof. G.K. Hovingh MD PhD

foto

Prof. MD PhD G.K. Hovingh

Position
Full Professor
Main activities
Education, Patient care, Research, Other
Specialisation
Lipid metabolism, Genetics
Focus of research
The focus of my research is the molecular basis of inherited dyslipidemias and novel therapies.

Key publications
  • Sjouke Barbara, Kusters D. Meeike, Kindt Iris, Besseling Joost, Defesche Joep C., Sijbrands Eric J. G., Roeters van Lennep Jeanine E., Stalenhoef Anton F. H., Wiegman Albert, de Graaf Jacqueline, Fouchier Sigrid W., Kastelein John J. P., Hovingh G. Kees Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome European heart journal 2015;36 (9):560-565 [PubMed]
  • Motazacker Mohammad Mahdi, Peter Jorge, Treskes Marco, Shoulders Carol C., Kuivenhoven Jan Albert, Hovingh G. Kees Evidence of a polygenic origin of extreme high-density lipoprotein cholesterol levels Arteriosclerosis, thrombosis, and vascular biology 2013;33 (7):1521-1528 [PubMed]
  • Besseling Joost, Kastelein John J. P., Defesche Joep C., Hutten Barbara A., Hovingh G. Kees Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus JAMA 2015;313 (10):1029-1036 [PubMed]
  • Hovingh G. Kees, Kastelein John J. P., van Deventer Sander J. H., Round Patrick, Ford John, Saleheen Danish, Rader Daniel J., Brewer H. Bryan, Barter Philip J. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial Lancet 2015;386 (9992):452-460 [PubMed]
  • Rader Daniel J., Hovingh G. Kees HDL and cardiovascular disease Lancet 2014;384 (9943):618-625 [PubMed]
All Publications
Research programmes

Prof. MD PhD G.K. Hovingh (Genetics and Pathology of Atherosclerosis)

Prof. MD PhD E.S.G. Stroes (Novel anti-atherogenic strategies targeting the vessel wall)

Prof. MD PhD J.J.P. Kastelein (Vascular Medicine)

Current research funding
  • AMC (Vrijgesteld)
  • Portola Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Stichting AMC Foundation (Vrijgesteld)
  • UBC Late Stage (UK) Limited
  • Vascular Research Network BV
  • Zealand Pharma A/S
  • ZonMw